DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure

Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications   (Posted by Tom Lamb at DrugInjuryWatch.com)   In April 2016 the FDA took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for these relatively new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class:  Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Nesina (alogliptin) Kazano (alogliptin and metformin) Oseni (alogliptin and pioglitazone) Qtern (dapagliflozin and saxagliptin) In connection with that DPP-4 diabetes drug label change as well as related earlier FDA actions, some medical researchers recently took a look at heart-related side effects reports submitted to FDA Adverse Event Reporting System (FAERS) from 2006 to 2015. From the Abstract for a subsequent medial journal article with their findings, in the Conclusions section: Postmarketing surveillance of…

Read more detail on Recent Products Liability posts –

This entry was posted in Products Liability and tagged , , , , , , , , , , . Bookmark the permalink.

Leave a Reply